| Elanco to Participate in the Upcoming Investor Conferences |
GREENFIELD, Ind. , May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. |
prnewswire.com |
2025-05-16 12:00:00 |
Czytaj oryginał (ang.) |
| Elanco: Deleveraging Takes Time |
Elanco's shares have been pressured due to pipeline delays and debt from the Bayer acquisition, causing cautious optimism despite recent valuation resets. The company focuses on animal health, with balanced pet and livestock products, but struggles with debt and underwhelming growth since acquiring Bayer's animal health business. Despite some sales growth and debt reduction efforts, EBITDA and earnings are declining, limiting enthusiasm for significant investment. |
seekingalpha.com |
2025-05-12 08:26:11 |
Czytaj oryginał (ang.) |
| Elanco price target raised to $11 from $9.50 at Leerink |
Leerink analyst Daniel Clark raised the firm's price target on Elanco to $11 from $9.50 and keeps a Market Perform rating on the shares. The firm says the company's quarter was solid, and its exposure to tariffs was less than many feared. These two factors vs. bearish positioning are likely driving a bit of a squeeze in shares today. The updated guide appears prudent to Leerink, factoring in potential downside from pharmaceutical tariffs as well as the full impact of China tariffs at current rates, net of mitigation efforts. Ultimately, Elanco continues to be a second half of 2025 and 2026 growth story, the firm argues. 07 May |
https://thefly.com |
2025-05-07 17:43:49 |
Czytaj oryginał (ang.) |
| Elanco Animal Health Incorporated (ELAN) Q1 2025 Earnings Call Transcript |
Elanco Animal Health Incorporated (NYSE:ELAN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Tiffany Kanaga - Head of Investor Relations Jeffrey Simmons - President and Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Jonathan Block - Stifel Michael Ryskin - Bank of America Andrea Alfonso - UBS Brandon Vazquez - William Blair Ekaterina Knyazkova - JPMorgan Navann Ty - BNP Paribas Mike DiFiore - Evercore ISI Erin Wright - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-07 16:52:39 |
Czytaj oryginał (ang.) |
| Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide |
Elanco Animal Health Incorporated ELAN reported first-quarter 2025 adjusted earnings per share of 37 cents. That's up 9% year over year. |
benzinga.com |
2025-05-07 15:03:27 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Elanco Animal Health (ELAN) Q1 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Elanco Animal Health (ELAN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-07 14:35:53 |
Czytaj oryginał (ang.) |
| Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates |
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.34 per share a year ago. |
zacks.com |
2025-05-07 12:35:36 |
Czytaj oryginał (ang.) |
| Elanco Animal Health Reports First Quarter 2025 Results |
Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results: Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growth Reported Net Income of $67 million, Adjusted Net Income of $184 million Adjusted EBITDA of $276 million, or 23.1% of Revenue Reported EPS of $0.13, Adjusted EPS of $0.37 Net leverage ratio of 4.4x Adjusted EBITDA Full Year 2025 Guidance: Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digits Raising 2025 innovation revenue target to $660 to $740 million Reported Net Loss of $(35) to $(7) million, maintaining guidance for Adjusted EBITDA of $830 to $870 million Reported Loss Per Share of $(0.07) to $(0.01), maintaining guidance for Adjusted EPS of $0.80 to $0.86 Outlook incorporates current estimate for tariff net impact of $16 to $20 million to Adjusted EBITDA and expected continued macro volatility, offset by a strong first quarter performance Expecting gross debt paydown of $450 to $500 million in 2025 2025 year-end net leverage ratio target improved to 3.9x to 4.3x, enabled by disciplined working capital management, more favorable foreign exchange rates, and lotilaner U.S. royalty monetization GREENFIELD, Ind. , May 7, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2025, provided guidance for the second quarter of 2025, and updated guidance for the full year 2025. |
prnewswire.com |
2025-05-07 10:27:00 |
Czytaj oryginał (ang.) |
| Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal |
Elanco Animal Health Incorporated ELAN on Monday announced the sale of certain future tiered royalties and commercial milestones associated with Xdemvy (lotilaner ophthalmic solution) 0.25% for the human health application of lotilaner to Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. |
benzinga.com |
2025-05-05 20:40:36 |
Czytaj oryginał (ang.) |
| Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown |
GREENFIELD, Ind. , May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. |
prnewswire.com |
2025-05-05 10:27:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out |
NEW YORK CITY, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accessnewswire.com |
2025-05-04 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Shareholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accessnewswire.com |
2025-05-01 14:00:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q1 Earnings Expected to Decline |
Elanco Animal Health (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:06:51 |
Czytaj oryginał (ang.) |
| ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Elanco Animal Health Incorporated (NYSE:ELAN) on behalf of long-term stockholders following a class action complaint that was filed against Elanco on October 7, 2024 with a Class Period from November 7, 2023 to June 26, 2024. Our investigation concerns whether the board of directors of Elanco have breached their fiduciary duties to the company. |
globenewswire.com |
2025-04-30 01:00:00 |
Czytaj oryginał (ang.) |
| Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accessnewswire.com |
2025-04-29 14:00:00 |
Czytaj oryginał (ang.) |
| Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accessnewswire.com |
2025-04-24 14:00:00 |
Czytaj oryginał (ang.) |
| Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco |
Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to detail his latest trades. |
youtube.com |
2025-04-23 17:16:58 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect |
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accessnewswire.com |
2025-04-22 14:00:00 |
Czytaj oryginał (ang.) |
| Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day |
National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease. Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo. |
prnewswire.com |
2025-04-22 12:27:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Stockholders to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accessnewswire.com |
2025-04-20 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Stockholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accesswire.com |
2025-01-02 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Investors to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accesswire.com |
2024-12-29 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Reach Out |
NEW YORK CITY, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accesswire.com |
2024-12-26 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Reach Out |
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accesswire.com |
2024-12-22 12:00:00 |
Czytaj oryginał (ang.) |
| Elanco to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
GREENFIELD, Ind. , Dec. 19, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 43rd Annual J.P. |
prnewswire.com |
2024-12-19 13:07:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect |
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. |
accesswire.com |
2024-12-18 20:30:00 |
Czytaj oryginał (ang.) |
| NYSE: ELAN Lawsuit Alert: Investors who lost money with Elanco Animal Health Incorporated shares should contact the Shareholders Foundation |
SAN DIEGO , Dec. 9, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a lawsuit is currently pending for certain investors in shares of Elanco Animal Health Incorporated (NYSE: ELAN). Long-Term investors who purchased shares of Elanco Animal Health Incorporated (NYSE: ELAN) prior to November 2023 and continue to hold any of those NYSE: ELAN shares also have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. |
prnewswire.com |
2024-12-09 23:55:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Elanco Animal Health Incorporated of Class Action Lawsuit and Upcoming Deadlines - ELAN |
NEW YORK, NY / ACCESSWIRE / December 7, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE:ELAN) and certain officers. The class action, filed in the United States District Court for the District Of Maryland, and docketed under 24-cv-02912 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. |
accesswire.com |
2024-12-07 14:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 6, 2024 in Elanco Lawsuit - ELAN |
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / If you suffered a loss on your Elanco Animal Health Incorporated (NYSE:ELAN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elanco-animal-health-incorporated-lawsuit-submission-form?prid=115246&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-06 18:30:00 |
Czytaj oryginał (ang.) |
| ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elanco Animal Health Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN) and certain of its officers. |
globenewswire.com |
2024-12-06 18:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on Elanco Animal Health Incorporated (ELAN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / If you suffered a loss on your Elanco Animal Health Incorporated (NYSE:ELAN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elanco-animal-health-incorporated-lawsuit-submission-form?prid=115199&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-06 14:15:00 |
Czytaj oryginał (ang.) |
| ELAN Deadline Today: Rosen Law Firm Urges Elanco Animal Health Incorporated (NYSE: ELAN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights |
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Elanco is an “animal health company that develops, manufactures, and markets products for pets and farm animals.” For more information, submit a form, email attorney Phillip Kim, or give us a. |
businesswire.com |
2024-12-06 13:51:00 |
Czytaj oryginał (ang.) |
| Elanco (ELAN) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action - Hagens Berman |
SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2024 / Animal health company Elanco (ELAN) and its most senior executives are the targets of a securities class action suit, alleging that they downplayed potential safety concerns related to Elanco's new oral Janus kinase inhibitor, Zenrelia, while overstating its prospects for a rapid U.S. market entry. Hagens Berman urges Elanco Animal Health Incorporated (NYSE:ELAN) investors who suffered substantial losses to submit your losses now. |
accesswire.com |
2024-12-06 13:45:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Elanco Animal Health Incorporated Investors of a Class Action Lawsuit and Upcoming Deadline - ELAN |
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / If you suffered a loss on your Elanco Animal Health Incorporated (NYSE:ELAN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elanco-animal-health-incorporated-lawsuit-submission-form?prid=115153&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-06 10:45:00 |
Czytaj oryginał (ang.) |
| ELAN CLASS ACTION DEADLINE IS TODAY: Elanco Investors are Alerted of December 6 Deadline in Securities Fraud Class Action – Contact BFA Law Now (NYSE:ELAN) |
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. |
globenewswire.com |
2024-12-06 10:15:00 |
Czytaj oryginał (ang.) |
| December 6, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - ELAN |
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / If you suffered a loss on your Elanco Animal Health Incorporated (NYSE:ELAN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elanco-animal-health-incorporated-lawsuit-submission-form?prid=115145&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-06 09:15:00 |
Czytaj oryginał (ang.) |
| FINAL REMINDER ELAN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Elanco Animal Health Incorporated Investors to Participate in the Class Action Lawsuit |
NEW YORK CITY, NY / ACCESSWIRE / December 6, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Elanco securities between November 7, 2023, and June 26, 2024, inclusive (the "Class Period"). |
accesswire.com |
2024-12-06 09:00:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Elanco Animal Health Incorporated (ELAN) - December 6, 2024 Deadline to Join - Contact Levi & Korsinsky |
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. |
prnewswire.com |
2024-12-06 07:45:00 |
Czytaj oryginał (ang.) |
| ELAN Deadline: ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Lawsuit |
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"), of the important December 6, 2024 lead plaintiff deadline. So what: If you purchased Elanco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
prnewswire.com |
2024-12-06 02:20:00 |
Czytaj oryginał (ang.) |
| ELAN LAWSUIT ALERT: Levi & Korsinsky Notifies Elanco Animal Health Incorporated Investors of a Class Action Lawsuit and Upcoming Deadline |
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / If you suffered a loss on your Elanco Animal Health Incorporated (NYSE:ELAN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elanco-animal-health-incorporated-lawsuit-submission-form?prid=115105&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-05 23:45:00 |
Czytaj oryginał (ang.) |